Crinetics Pharmaceuticals, Inc. (CRNX) intrinsic value & 10-year financials
Crinetics Pharmaceuticals, Inc. (CRNX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 33.0% a year to $7.7M, with an average return on invested capital of -34.2%.
- Graham intrinsic value
- —
- Revenue (FY2025)
- $7.7M
- Revenue growth (10-yr CAGR)
- 33.0%
- ROIC (10-yr avg)
- -34.2%
- Free cash flow (FY2025)
- -$383.7M
CRNX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $7.7M | -$465.3M | -$4.95 | -$383.7M | -6714.8% | -50.7% |
| FY2024 | $1.0M | -$298.4M | -$3.69 | -$229.8M | -32613.5% | -41.4% |
| FY2023 | $4.0M | -$214.5M | -$3.69 | -$171.0M | -5547.2% | -54.5% |
| FY2022 | $0 | -$163.9M | -$3.15 | -$116.9M | — | -79.9% |
| FY2021 | $0 | -$107.6M | -$2.80 | -$89.0M | — | -100.6% |
| FY2020 | $71.0K | -$73.8M | -$2.42 | -$62.2M | -105567.6% | -92.8% |
| FY2019 | $1.2M | -$50.4M | — | -$46.9M | -4512.3% | -65.9% |
| FY2018 | $2.4M | -$27.1M | — | -$20.5M | -1182.5% | -39.5% |
| FY2017 | $2.0M | -$9.2M | — | -$9.8M | -446.3% | 86.0% |
| FY2016 | $589.0K | -$6.0M | — | -$5.7M | -1026.1% | 97.4% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Crinetics Pharmaceuticals, Inc. is a consistent compounder, expanding top-line revenue at 33.1% annually over the past decade.
Crinetics Pharmaceuticals, Inc. has historically struggled to out-earn its cost of capital, averaging just -69.4% ROIC.
Crinetics Pharmaceuticals, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Crinetics Pharmaceuticals, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-164.42 per share.